Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Structural Characterization of the Self-Association of the Death Domain of p75NTR

  • Qianhui Qu,

    Affiliations National Key Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China, Graduate University of Chinese Academy of Sciences, Beijing, China

  • Jun Chen,

    Affiliations Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China, Graduate University of Chinese Academy of Sciences, Beijing, China

  • Yizhi Wang,

    Affiliations National Key Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China, Graduate University of Chinese Academy of Sciences, Beijing, China

  • Wenjun Gui,

    Affiliations National Key Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China, Graduate University of Chinese Academy of Sciences, Beijing, China

  • Li Wang,

    Affiliations Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China, Graduate University of Chinese Academy of Sciences, Beijing, China

  • Zusen Fan,

    Affiliation Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China

  • Tao Jiang

    Affiliation National Key Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China

Structural Characterization of the Self-Association of the Death Domain of p75NTR

  • Qianhui Qu, 
  • Jun Chen, 
  • Yizhi Wang, 
  • Wenjun Gui, 
  • Li Wang, 
  • Zusen Fan, 
  • Tao Jiang


The neurotrophin receptor p75NTR conveys multiple signals via its intracellular death domain. However, how the death domain is activated and interacts with downstream adaptors remains unclear. Here, we report two crystal structures of the p75NTR death domain in the form of a non-covalent asymmetric dimer and a Cys379-Cys379 disulfide bond linked symmetric dimer, respectively. These two dimer arrangements have not previously been observed in other death domain-containing proteins. Further analysis shows that both the Cys379-Cys379 disulfide linked and non-covalent full-length p75NTR dimers are present on the cell surface. These observations suggest that various oligomers may exist simultaneously on the cell surface, and that p75NTR activation and signalling may be modulated by neurotrophins or other factors via inducing a shift of the equilibrium between different oligomeric states.


Neurotrophins are a family of secreted growth factors essential for early stage innervation and maintenance of the adult vertebrate nervous system. They interact with two different types of cell surface receptors, the selective Trk receptor tyrosine kinases and p75NTR, which binds to all neurotrophins with equal affinity [1], [2]. Unlike the Trk receptors, which possess characteristic tyrosine kinase domains, p75NTR lacks intrinsic kinase activity. Glycosylated extracellular cysteine-rich domains serve as the ligand-binding site of p75NTR, while its intracellular region consists of a flexible juxtamembrane segment (residues 280–333), a globular death domain (residues 334–418), and a short tail (residues 419–425) [3], [4]. In addition to its expression in the central and peripheral nervous systems, p75NTR is also widely expressed in non-neuronal cells, including immune cells, smooth muscle and epithelial cells, and fibroblasts [5]. In addition to neurotrophins, p75NTR can recognise a number of novel ligands such as β-amyloid peptides, prion peptides and myelin-associated inhibitors, in cooperation with their related co-receptors [6], [7], [8], [9], [10]. Signals in distinct pathways mediated by p75NTR are conveyed by the recruitment and release of multiple cytoplasmic adaptor proteins such as neurotrophin receptor interacting factor (NRIF), neurotrophin receptor interacting MAGE homolog (NRAGE) and tumor necrosis factor receptor (TNFR) associated factor 6 (TRAF6), and result in the activation of a wide array of downstream signalling molecules (e.g., nuclear factor kappa B (NF-kB), c-jun N-terminal kinase (JNK) or caspases) [11], [12]. Through these downstream events, p75NTR regulates various cellular functions including cell apoptosis, survival, neurite outgrowth and synaptic plasticity, making it an important target for the treatment of neurodegenerative and other diseases [13], [14], [15], [16], [17], [18].

The monomeric form of the intracellular death domain of p75NTR, solved by NMR, displays a folding module that is similar to death domain superfamily members such as Fas and TNFR, in spite of low sequence identity [3]. However, these proteins show different oligomerization patterns. Fas and TNFR bind trimeric ligands to induce the trimer- or oligomerization of their intracellular death domains, while biochemical data and the structures of the p75NTR ectodomain complex with NT3 [19] and proNGF [20] have demonstrated that p75NTR binds dimeric neurotrophins and that dimerization of the p75NTR intracellular region is functionally significant [21]. Therefore, the association mechanism of the death domain of p75NTR is likely to be different from that of Fas and TNFR. Recently, Vilar and colleagues reported that p75NTR could exist as a disulfide bond-linked dimer before ligand binding via a highly conserved Cys257 residue in its transmembrane region, and the dimer proportion in transfected cells didn't change upon NGF binding [22]. Fluorescence resonance energy transfer (FRET) experiments also revealed that close association of p75NTR intracellular domains was transiently disrupted by conformational changes that occured upon ligand binding. These results suggest that neurotrophins activate p75NTR by a mechanism involving the rearrangement of intracellular domains, in which Cys257 acts as a fulcrum, mediating the propagation of conformational changes (“Snail-Tong”model [22]). However, how the p75NTR death domain associates with itself or with other proteins is still unclear.

To gain insight into the mechanism of p75NTR regulation, we determined the structural and functional properties of the following truncations involving the rat p75NTR intracellular region: p75DD (residues 334–418), p75CTD (334–425), p75ICD (280–425), and p75DD-Fusion (a chimera of the p75NTR death domain and a p75-interacting peptide from NRIF) (Fig. 1A). By introducing cysteine modifications using 5,5′-dithio-bis(2-nitrobenzoic acid) (DTNB), we obtained the crystal structures of the p75DD and p75DD-Fusion proteins. In the crystal structure of p75DD, we observed an asymmetric dimer in which the H5 and H6 helices of one death domain monomer juxtaposed against the H3 helix of another. The structure of the p75DD-Fusion protein revealed that the p75NTR death domain presented as a novel symmetric dimer linked via an inter-chain disulfide bond between Cys379 residues. Further in vitro binding experiments showed that one downstream adaptor protein, RIP2, could only interact with the monomer, not the symmetric dimer of the p75NTR death domain; while a synthetic NRIF peptide bound to both monomer and dimer without significant difference in apparent affinity. Biochemical analyses indicated the Cys379-Cys379 disulfide linked p75NTR dimer could exist on the 293T cell surface. Considering these data together with previous biochemical evidence, we proposed a model that multiple oligomerization patterns of p75NTR present on the cell surface may confer different regulation levels to the p75NTR signalling pathway.

Figure 1. Solution features of different constructs of p75NTR intracellular region.

(A) Schematic diagram of the p75NTR constructs used in this work. (B) Size-exclusion chromatography profiles of these constructs on Superdex 75 column. All proteins elute as mixture of dimer and monomer, while the dimer portion of p75DD is not that obvious.


The oligomeric behavior of the four p75NTR constructs in solution is shown in Figure 1B; all constructs are present as a mixture of monomers and dimers. Intriguingly, p75DD exists less frequently as a dimer, implying that the short C-terminal tail (residues 419–425) in p75NTR is important for dimer formation. We failed to obtain crystals until the proteins were treated with DTNB, a cysteine-modifying reagent that generates a homogeneous oxidised state and stabilises local fluctuations [23]. After treatment, suitable p75DD and p75DD-Fusion protein crystals were obtained for structural analysis.

A unique asymmetric interaction occurs between death domains of p75NTR

The structure of p75DD was solved by molecular replacement using the NMR structure (PDB 1NGR) as the search model. After model building and refinement, we were able to trace amino acids 334–417 of the death domain. The overall fold of the p75DD monomer is similar to the NMR structure with a small RMSD value (1.44 Å) of Cα traces (Fig. S1A). Briefly, the N-terminal segment is close to the C-terminus, and six helices connected by short loops encircle into a tight globular structure, with the third helix (H3) extending slightly away. In the crystal lattice, neighbouring death domains stack to form asymmetric dimers, with the H5 and H6 helices of one monomer (A) juxtaposed against the H3 helix of the other monomer (B), forming interfaces enriched with polar and hydrophobic interactions, e.g. R404 from monomer A interacts with S373, H376 and E377 of monomer B (Fig. 2), in agreement with speculation that the H5 helix is important for the association of p75NTR with other proteins [24]. DTNB-modified Cys379 and Cys416 in p75DD stabilise the monomer structure, while these residues are not involved in monomer-monomer interactions (Figs. S1B and S1C).

Figure 2. Asymmetric dimeric interface in the p75DD crystal lattice.

Details of the asymmetric dimer interface are shown in the left expanded view. The interfacial electrostatic distribution is shown in the two right expanded views, with residues involved in hydrophobic interactions highlighted as sticks.

The death domain, a versatile protein interaction module, plays an essential role in the assembly and activation of apoptotic and inflammatory complexes such as the DISC, PIDDosome and TLR/IL-1 receptor complex [25]. While the monomeric structures of most of these death domains have been solved via NMR under acidic conditions that might disrupt the oligomeric capacity of the proteins, several death domain complex structures have been elucidated by X-ray crystallography [26], [27], [28], [29], [30]. An intriguing feature prevalent among these complex structures is that death domains, such as those in the Pelle-Tube complex [26] and Fas/FADD oligomer [30], contact each other in an asymmetric fashion. Different monomer-monomer interfaces between death domains have been categorised into the following three types based on their contact region: type I (H1/H4: H2/H3), type II (H4/H4–H5 loop: H6/H5–H6 loop) and type III (H3: H1–H2 loop/H3–H4 loop) [27], [31]. In our p75DD structure, the size of buried solvent accessible area (320 Å2 [32]; Shape complementarity value = 0.75 [33]) of the asymmetric dimer was comparable to that of other death domain complexes, but it had a novel H5/H6:H3 asymmetric interface (Fig. S2).

The symmetric dimer of the p75NTR death domain is linked via an inter-chain disulfide bond

The p75DD-Fusion protein was initially designed as a chimera between the p75NTR death domain and a p75NTR-interacting peptide from NRIF, connected by an 18-amino-acid linker (Fig. 1A). NRIF is the first protein identified to associate with the intracellular domain of p75NTR and mediates p75NTR-dependent neuronal death [34], [35]. A previous study demonstrated that the p75NTR-binding region spans residues 521–661, a flexible loop structure, in NRIF [34]. We constructed this loop region of NRIF preceded by a glutathione S-transferase tag and co-expressed it with the His6-tagged p75DD protein in E. coli. However, progress was hampered by severe proteolysis of NRIF. After many attempts, we found that a short NRIF peptide spanning residues 552–577 (determined by mass spectrometry) co-eluted with the p75DD protein during size exclusion chromatography. We then generated the p75DD-Fusion protein and successfully crystallised the dimer fraction (Figs. S3A and S3B). However, mass spectrometry indicated that, unfortunately, only the p75NTR death domain and a portion of the linker residues (GSGSGSGS) were retained in p75DD-Fusion crystals (Fig. S3C). Even so, only the death domain portion (residues 335–417) was visible in the final electron density map. For ease of description, the structure solved was still named p75DD-Fusion.

Asymmetric units of the p75DD-Fusion crystal contain two monomers symmetrically related by a non-crystallographic two-fold rotation axis. Inspection of the buried interface (552 Å2) shows that an inter-chain disulfide bond is formed between the Cys379 residues from each monomer (Fig. 3), while Cys416 is modified by DTNB and is not involved in monomer-monomer interactions (Fig. S1B). Several residues distributed on the interface interact via hydrogen bonds or hydrophobic interactions through both main chain and side chain residues. For example, Arg382 on the amino side of H4 interacts with Glu346 and Glu349 from the first helix. The loop region between H3 and H4 of one death domain (monomer B) protrudes into the H1–H2 and H3–H4 regions of the other (monomer A), and vice versa, forming a primarily hydrophobic cave surrounded by polar residues (Fig. 3).

Figure 3. Disulfide linked symmetric dimer of p75NTR death domain.

The 2Fo-Fc electron density (contour σ = 1.6) shows the inter-chain disulfide bond (orange) formed by the Cys379 residues from both monomers (right expanded view). Details of the symmetric dimer interface are shown below in two expanded views. The inter-chain disulfide bond formed between Cys379 residues is highlighted as orange sticks.

Symmetric association of death domains also occurs in the tetrameric structure of the Fas/FADD complex [28]. However, the p75NTR death domain and the Fas death domain dimerization are significantly different (Fig. 4A). First, the symmetric p75NTR death domain dimer is crystallised under neutral conditions with the overall structure resembling the NMR model, while the Fas/FADD tetramer crystals are gained at pH 4.0, in which the Fas death domain is in an “open” state where the sixth helix shifts and fuses with the fifth helix to form a single long helix (stem helices), showing a large conformational change relative to the typical globular structure of its native state. Second, the p75NTR symmetric death domain dimer is linked by an inter-chain disulfide bond, whereas the Fas death domain dimer is associated by non-covalent interactions between the stem helices (residues 287–318) and C-helices (a new formed helix, residues 327–334). It is noteworthy that a later NMR study suggests a different 5∶4 or 5∶5 Fas/FADD complex in solution under near physiological condition [36]. Third, the p75NTR symmetric death domain dimer is likely in a self-inhibitory state, according to the Snail-Tong model [22], while the Fas death domain is in an apparently activated state when complexed with FADD. Sequence alignment also shows limited similarity of residues involving in dimeric interface between p75NTR symmetric dimer and Fas-Fas dimer (Fig. 4B). These differences suggest that the symmetric p75NTR death domain dimer represents a new assembly pattern for the death domain containing proteins.

Figure 4. Oligomerization pattern comparison of p75NTR death domain with other death domain containing proteins.

(A) The symmetric p75NTR death domain dimer is different from the symmetric death domain dimer observed in tetrameric Fas/FADD complex (PDB 3ZEQ). (B) Sequence alignment of p75NTR death domain with other death domain containing proteins. Secondary structure of p75NTR death domain is shown above the sequences, and residues involved in p75NTR death domain asymmetric and symmetric dimer interfaces are indicated with cyan circle and purple pentacle above, respectively. Residues involved in three classic asymmetric interface types are highlighted as: Type I, green; Type II, blue; Type III, red; respectively. Residues important for dimerization of Fas-Fas in Fas/FADD tetrameric complex (PDB 3ZEQ) are boxed in red outline. The utmost important Cys379 for disulfide-linked dimerization of p75NTR death domain was highlighted with orange pentacle.

The Cys379 residue is important for dimerization of the intracellular domain of p75NTR

Non-reducing SDS-PAGE and mutagenesis experiments confirm the existence of an inter-chain disulfide bond in the p75DD-Fusion construct. DTT and β-ME reduce the p75DD-Fusion, and the substitution of Cys379 with serine (C379S) completely abolishes the dimerization of p75DD-Fusion (Fig. S3). Interestingly, the R382A mutation reduces the dimer fraction of p75DD-Fusion, indicating its importance in p75NTR death domain dimerization (Fig. S3C). We further examine the disulfide-bond formation of p75ICD and p75CTD in solution. We find that increasing β-ME concentrations decreases the amounts of dimers of both the p75ICD and p75CTD proteins (Fig. S4). Furthermore, the C379S mutation of p75CTD largely prevents dimerization (Fig. S4C), suggesting that most of the p75CTD and p75ICD dimers in solution are disulfide-bond linked dimers.

Furthermore, HEK 293T cells are transfected to test the effects of Cys379 mutation on full-length p75NTR without ligand treatment. The single mutation of Cys257 or Cys379 only slightly reduces the dimer fraction, while double mutation of Cys257 (C257A) and Cys379 (C379S) nearly abolishes p75NTR dimerization (Fig. 5A). This suggests that the Cys379-Cys379 disulfide bond exist in non-ligand bound cell surface p75NTR dimers.

Figure 5. A model of p75NTR signalling regulation.

(A) Cell surface expression of disulfide-linked p75NTR dimers (dim) and monomers (mon) in transfected HEK 293T cells by probing of p75NTR immunoprecipitates treated with or without DTT. An unspecific band of MW≈130 k Da was observed in all samples and controls. (B) The binding of p75CTD monomer and symmetric dimer with the RIP2 CARD domain were analyzed by bio-layer interferometry (BLI). Binding kinetics of p75CTD monomer with the RIP2 CARD domain of different concentrations were further recorded. (C) Proposed model of p75NTR activation. Different oligomerization patterns of p75NTR such as monomers, non-symmetric dimers and symmetric dimers may exist simultaneously on the cell surface (based on the relative position of the intracellular domains). Regulation may result from turnover between non-symmetric dimer and symmetric dimer. An oxidation-reduction equilibrium may exist between the covalent symmetric dimer (Cys379-Cys379 disulfide bond) and the non-covalent symmetric dimer, which might confer another level of regulation through oxidative stress.

Asymmetric and symmetric p75NTR death domain dimers have largely distinct surface electrostatic distributions (Fig. S5), implying an altered preference for downstream adaptors. We initially planned to determine the binding characteristics of these dimers with two downstream adaptors, receptor-interacting protein-2 (RIP2) and NRIF. However, as it was not possible to prepare a homogeneous asymmetric dimer, we measured the binding kinetics of the monomer and symmetric p75CTD dimers instead. The p75CTD monomer is obtained by double mutations of the Cys379 and Cys416 residues to serine, while the symmetric dimer is purified iteratively from the dimer fraction of the C416S mutant of p75CTD protein. RIP2 is an adaptor protein containing an N-terminal Ser/Thr kinase domain and a C-terminal caspase recruitment domain (CARD). It has been shown that RIP2 binds to p75NTR via its CARD domain, though only after p75NTR is activated by NGF treatment [37]. Intriguingly, the bio-layer interferometry (BLI) assay shows the RIP2 CARD domain selectively binds to the p75CTD monomer, but not the dimer (Fig. 5B), while the above-mentioned p75NTR-interacting peptide of NRIF could associate with both the monomer and the symmetric p75CTD dimer with relatively low affinities measured by surface plasmon resonance (SPR) (kD≈10−5 M; Figs. S4D and S4E), which is approximately 100-fold weaker than the binding of RIP2 CARD domain with the p75CTD monomer. These data indicate that the various oligomeric conformations of the p75NTR intracellular region have different binding features.


As a member of the TNFR superfamily, p75NTR signalling, like other non-catalytic receptors, was assumed to be mediated via ligand-induced oligomerization of intracellular domains, while the discovery of pre-existing dimers of p75NTR on the cell surface provided new clues to understand the regulation of p75NTR signalling [22]. Still, questions arise about whether there is equilibrium between monomers and dimers of p75NTR, how the dimer is assembled, and how the intracellular domains of the dimer interplay to trigger the signal cascade of p75NTR.

Here we described two oligomeric arrangements of the p75NTR death domain, namely an asymmetric non-covalent dimer and a covalent symmetric dimer. Further analysis reveals the presence of both non-covalent dimer and Cys379-Cys379 disulfide bond linked full-length p75NTR dimer on the cell surface of HEK 293T cells. It is still unknown whether the asymmetric dimer observed in the crystal structure is one form of the functionally relevant dimers on the cell surface, however, it provides some avenues for further investigation (Fig. 4B). In addition to the monomeric p75NTR, various oligomeric forms of p75NTR such as the symmetric dimer with or without an inter-chain disulfide bond (i.e., Cys379-Cys379), and other potential non-covalent dimers may simultaneously exist on the cell surface prior to ligand binding (Fig. 5C). These multiple assembly patterns may fine-tune the regulation of p75NTR activation. Though p75NTR lacks intrinsic kinase activity, its activation mechanism may be similar to that of epidermal growth factor receptor (EGFR) kinase [38] in that their asymmetric and symmetric dimers correspond to different functional states.

Another level of p75NTR regulation may be conferred by oxidative stress. Cysteine residues are believed to mediate cellular responses to redox conditions via both detecting oxidative changes and transducing conformational alterations in protein structure and function. A common mechanism underlying the sensitivity of cysteines to redox status is the formation of disulfide bonds. Recent studies have shown that the intracellular domain confers protection on p75NTR against oxidative stress-induced apoptosis, independent of its extracellular domain or ligand binding [39], [40]. The formation of disulfide bonds between p75NTR death domains suggests that the Cys379 residue may function as a redox sensor. Although the Cys379 residue of p75NTR is not conserved in other death domain-containing proteins (Fig. 4B), given the dimerization or oligomerization properties of death domains, it is worthwhile to further investigate whether disulfide bonds can be formed between different death domains under certain redox conditions.

In conclusion, our results reveal the key residues involved in the formation of different p75NTR oligomers, and provide new insights into the mechanism of p75NTR activation. In addition to the significant intracellular domain rearrangement that can be induced by neurotrophin binding, the ratio of inactive covalent dimers to active non-covalent dimers could be affected by redox conditions. Binding of neurotrophins and other factors to p75NTR could then result in a shift of the equilibrium among different oligomeric states, thereby encoding multiple functional sates of p75NTR.

Materials and Methods

Protein expression and purification

Several constructs of the p75NTR intracellular region, p75DD (residues 334–418), p75CTD (334–425) and p75ICD (280–425), were amplified respectively from a rat p75NTR cDNA and constructed into pET24a vector with C-terminal His6 tag. Proteins were over-expressed in the E. coli BL21 strain and purified with Ni-NTA column and size-exclusion chromatography using a Hepes-KOH buffer (pH 7.0) containing 100 mM KCl, 5% glycerol and 1 mM EDTA. DTNB powder was dissolved in the same buffer to 2 mM concentration, and was added to protein solution at a molar ratio of 5∶1 between DTNB and proteins. After modification with DTNB, proteins were concentrated to 40 mg/mL to screen crystal growth conditions.

The p75DD-Fusion protein constructed from p75NTR death domain (residues 334–418) and a 26-amino-acid sequence (residues 552–577) of the NRIF protein were fused with an 18-amino-acid linker coding for the sequence GSEFGSGSLVPRGSGSGS. These proteins were also overexpressed in the E.coli BL21 strain and purified in a Hepes-NaOH buffer (pH 7.5) with 100 mM NaCl, 5% glycerol and 1 mM EDTA. Proteins used for crystallization were concentrated to 20 mg/mL after DTNB treatment.

For binding tests, NRIF peptide (residues 552–577) was chemically synthesized. Human RIP2 CARD domain (residues 438–524) was constructed into pET24a vector with C-terminal His6 tag and overexpressed in E. coli. Purification of RIP2 CARD domain was similar to that of p75DD.

Crystallization and data collection

P75DD and p75DD-Fusion protein crystals were grown at 4°C using the sitting-drop vapour diffusion method. Crystals of p75DD were obtained using 0.1 M Bis-Tris propane pH 7.0 and 1.2 M sodium citrate, while p75DD-Fusion crystals were grown in 0.1 M Bis-Tris propane pH 7.0 and 1.4 M sodium malonate pH 7.0. All crystals were harvested directly from the crystallization drop and flash-frozen in liquid nitrogen. Diffraction data for p75DD crystals were collected at 100K in-house and processed with iMosflm [41]. Data collection for p75DD-Fusion crystals was conducted at the BL17U beamline at the Shanghai Synchrotron Radiation Facility (SSRF, China) and integrated with the HKL2000 suite [42].

Structure determination and refinement

The structures of p75DD and p75DD-Fusion were solved by molecular replacement via MOLREP [43], using the NMR structure of p75NTR death domain (PDB 1NGR) as the initial search model. The residual group of the DTNB reagent (MNB) was sculpted with Sketcher [44]. The model was built with ARP/wARP and improved by cycles of manual rebuilding and refinement with REFMAC5 and Coot [45], [46], [47]. The quality of the final structure was evaluated with PROCHECK [48]. Statistics for data collection and refinement are summarized in Table 1.

In vivo detection of p75NTR dimerization

A full-length rat p75NTR construct in a pCDNA3 vector with an N-terminal hemagglutinin (HA) epitope tag was a generous gift from Prof. Bruce Carter and Carlos Ibanez. Mutations were introduced by site-directed mutagenesis and verified by DNA-sequencing. 293T human embryonic kidney fibroblasts were cultured in DMEM. Wildtype and mutants plasmids were transiently transfected into 293T cells. After 48 h, cells were harvested and lysed in 40 mM Tris (pH 7.6) buffer containing 150 mM NaCl, 0.5% NP-40, 10% glycerol and a protease inhibitor cocktail. Cell lysates were subjected to immunoprecipitation in the lysis buffer using an anti-HA monoclonal antibody. The precipitated proteins were boiled with reduced (DTT+) or non-reduced (DTT−) SDS loading buffer before being detected by immunoblotting with anti-HA monoclonal antibody.

Binding assays: bio-layer interferometry

The binding kinetics of the p75CTD monomer or dimer proteins to the CARD domain of RIP2 were measured by bio-layer interferometry on an Octet (ForteBio). A double cysteine residue mutant (C379S/C416S) was used as the p75CTD monomer, while the p75CTD dimer used in these experiments was the dimer of the C416S mutant. Streptavidin High Binding FA biosensors were loaded with biotinylated-p75CTD proteins in 10 mM PBS (pH 7.4) containing 0.1 mg/ml BSA and 0.002% (v/v) Tween. Loaded biosensors were first washed and transferred to wells containing CARD proteins at concentrations of 5 µM in kinetic buffer (50 mM Hepes-NaOH pH 7.5, 100 mM NaCl, 5% glycerol and 1 mM EDTA), and initial results showed no affinity for dimer proteins. We then transferred the biosensors with monomer proteins to wells containing the CARD protein at concentrations of 20 µM, 10 µM, 5 µM and 2 µM in kinetic buffer. Association and dissociation kinetics were recorded for 5 min and 10 min, respectively. Kinetic parameters (kon and koff) and affinities (kD) were calculated from a non-linear fit of the data using the Octet instrument.

Binding assays: surface plasmon resonance

Experiments to characterize the binding of p75CTD proteins and the NRIF 26-amino-acid peptide were conducted at 25°C using a Biacore 3000 SPR instrument (Biacore Life Sciences), equilibrated in running buffer containing 50 mM Hepes-KOH (pH 7.5), 100 mM KCl, 5% glycerol and 0.005% (v/v) Tween-20. P75CTD monomer and dimer proteins were coupled onto a CM-5 chip at equal molarities, and analytes were serially diluted in running buffer.

Supporting Information

Figure S1.

DTNB stabilizes the p75NTR death domain. (A) Superimposition of different structural models of the p75NTR death domain. The NMR model is shown in grey, one monomer of the p75DD crystal in green and one monomer of the p75DD-Fusion crystal in purple. (B) The MNB groups, produced by reduction of proteins with DTNB, covalently bind to the free cysteine residues of p75DD and p75DD-Fusion. (C) The polar moieties (−NO2 and −CO2) and the benzene ring of MNB interact with the surrounding residues of p75DD.



Figure S2.

New asymmetric interface. The interface of p75NTR death domain asymmetric dimer is different from three classic types of asymmetric interaction of death domain family, which are exemplified by Tube/Pelle complex (PDB 1D2Z) and Fas/FADD oligomer (PDB 3OQ9). The regions involved in classic asymmetric interface are indicated with blue dash circles. Residues important for the asymmetric interaction of these complexes exhibit limited conservation, as shown in Figure 4B.



Figure S3.

Biochemical features of the p75DD-Fusion protein. (A) The eluted dimer portion of p75DD-Fusion was influenced by β-ME, not DTNB. (B) p75DD-Fusion proteins form dimer via disulfide bond, as determined by SDS-PAGE in the presence/absence DTT condition. (C) Mass analysis shows degradation of p75DD-Fusion (MW≈10.7 kD) observed in the crystal, but not in solution. Mutations of the symmetrical dimer interface residues of p75DD-Fusion profiled via size exclusion chromatography (D). Mutation of C379S completely abolished the dimer fraction, and the R382A mutation also decreased the dimer peak. Notably, the Pro380 residue of the H3–H4 loop region might be important to the structural stability of the entire p75DD-Fusion protein because the P380V mutant is prone to aggregation.



Figure S4.

Distinct surface properties of symmetric dimer and asymmetric dimer. The N termini of the symmetric dimer (A) and asymmetric dimer (B) are colored in blue and point together towards the membrane (front view, membrane planar parallel to the paper). The distribution of the surface electrostatic potential for the symmetric dimer is different from that of the asymmetric dimer, viewed from near membrane side (top-view) and off membrane side (bottom-view).



Figure S5.

Features of the p75NTR intracellular domain and C-terminal domain. (A) Monomer/dimer transition of p75ICD at various concentrations of β-ME. (B) The p75CTD protein shows similar elution profile to p75ICD as the β-ME changes. (C) The cysteine mutants of p75CTD exhibit different oligomerization. Evidently, the Cys379 residue is important for p75CTD dimerization in solution. (D, E) Similar binding affinities of p75CTD dimer and monomer with NRIF peptide, measured by SPR. Almost equal molar concentrations of p75CTD monomer and dimer proteins were captured on a CM5 chip, and various concentrations of NRIF peptide (chemically synthesized) flowed over the chip in a BIACore 3000 machine.




We thank Y. Chen and T. Chen for assistance with SPR and BLI analysis. We thank the staff of the Shanghai Synchrotron Radiation Facility beamline 17 U for assistance with data collection. We thank P. Wu and P. Xue for useful suggestions in MS analysis.

Author Contributions

Conceived and designed the experiments: QHQ TJ. Performed the experiments: QHQ JC YZW WJG LW. Analyzed the data: QHQ JC ZSF TJ. Contributed reagents/materials/analysis tools: ZSF. Wrote the paper: QHQ TJ.


  1. 1. Chao MV (2003) Neurotrophins and their receptors: a convergence point for many signalling pathways. Nature Reviews Neuroscience 4: 299–309.
  2. 2. Reichardt LF (2006) Neurotrophin-regulated signalling pathways. Philosophical Transactions of the Royal Society B: Biological Sciences 361: 1545.
  3. 3. Liepinsh E, Ilag LL, Otting G, Ibanez CF (1997) NMR structure of the death domain of the p75 neurotrophin receptor. EMBO J 16: 4999–5005.
  4. 4. Underwood CK, Coulson EJ (2008) The p75 neurotrophin receptor. The International Journal of Biochemistry & Cell Biology 40: 1664–1668.
  5. 5. Frossard N, Freund V, Advenier C (2004) Nerve growth factor and its receptors in asthma and inflammation. European Journal of Pharmacology 500: 453–465.
  6. 6. Hempstead BL (2002) The many faces of p75NTR. Curr Opin Neurobiol 12: 260–267.
  7. 7. Roux PP, Barker PA (2002) Neurotrophin signaling through the p75 neurotrophin receptor. Prog Neurobiol 67: 203–233.
  8. 8. Nykjaer A, Willnow TE, Petersen CM (2005) p75NTR–live or let die. Curr Opin Neurobiol 15: 49–57.
  9. 9. Ben-Zvi A, Ben-Gigi L, Klein H, Behar O (2007) Modulation of semaphorin3A activity by p75 neurotrophin receptor influences peripheral axon patterning. The Journal of Neuroscience 27: 13000.
  10. 10. Lim YS, McLaughlin T, Sung TC, Santiago A, Lee KF, et al. (2008) p75NTR mediates ephrin-A reverse signaling required for axon repulsion and mapping. Neuron 59: 746–758.
  11. 11. Coulson EJ, Reid K, Bartlett PF (1999) Signaling of neuronal cell death by the p75NTR neurotrophin receptor. Mol Neurobiol 20: 29–44.
  12. 12. Blochl A, Blochl R (2007) A cell-biological model of p75NTR signaling. J Neurochem 102: 289–305.
  13. 13. Krygier S, Djakiew D (2001) The neurotrophin receptor p75NTR is a tumor suppressor in human prostate cancer. Anticancer Res 21: 3749–3755.
  14. 14. Allen J, Khwaja F, Djakiew D (2004) Gene therapy of prostate xenograft tumors with a p75NTR lipoplex. Anticancer Res 24: 2997–3003.
  15. 15. Nordell VL, Lewis DK, Bake S, Sohrabji F (2005) The neurotrophin receptor p75NTR mediates early anti-inflammatory effects of estrogen in the forebrain of young adult rats. BMC Neurosci 6: 58.
  16. 16. Zhou XF, Li HY (2007) Roles of glial p75NTR in axonal regeneration. J Neurosci Res 85: 1601–1605.
  17. 17. Fujii T, Kunugi H (2009) p75NTR as a therapeutic target for neuropsychiatric diseases. Curr Mol Pharmacol 2: 70–76.
  18. 18. Zeng F, Lu JJ, Zhou XF, Wang YJ (2011) Roles of p75NTR in the pathogenesis of Alzheimer's disease: A novel therapeutic target. Biochem Pharmacol
  19. 19. Gong Y, Cao P, Yu HJ, Jiang T (2008) Crystal structure of the neurotrophin-3 and p75NTR symmetrical complex. Nature 454: 789–793.
  20. 20. Feng D, Kim T, Ozkan E, Light M, Torkin R, et al. (2010) Molecular and structural insight into proNGF engagement of p75NTR and sortilin. J Mol Biol 396: 967–984.
  21. 21. Wang JJ, Rabizadeh S, Tasinato A, Sperandio S, Ye X, et al. (2000) Dimerization-dependent block of the proapoptotic effect of p75NTR. J Neurosci Res 60: 587–593.
  22. 22. Vilar M, Charalampopoulos I, Kenchappa RS, Simi A, Karaca E, et al. (2009) Activation of the p75 neurotrophin receptor through conformational rearrangement of disulphide-linked receptor dimers. Neuron 62: 72–83.
  23. 23. Mi W, Li L, Su XD (2008) 5, 5′-Dithio-bis (2-nitrobenzoic acid) modification of cysteine improves the crystal quality of human chloride intracellular channel protein 2. Biochemical and Biophysical Research Communications 368: 919–922.
  24. 24. Yamashita T, Tohyama M (2003) The p75 receptor acts as a displacement factor that releases Rho from Rho-GDI. Nat Neurosci 6: 461–467.
  25. 25. Park HH, Lo YC, Lin SC, Wang L, Yang JK, et al. (2007) The death domain superfamily in intracellular signaling of apoptosis and inflammation. Annual Review of Immunology 25: 561.
  26. 26. Xiao T, Towb P, Wasserman SA, Sprang SR (1999) Three-dimensional structure of a complex between the death domains of Pelle and Tube. Cell 99: 545–555.
  27. 27. Park HH, Logette E, Raunser S, Cuenin S, Walz T, et al. (2007) Death domain assembly mechanism revealed by crystal structure of the oligomeric PIDDosome core complex. Cell 128: 533–546.
  28. 28. Scott FL, Stec B, Cristina Pop M (2008) The Fas–FADD death domain complex structure unravels signalling by receptor clustering. Nature 457: 1019–1022.
  29. 29. Lin SC, Lo YC, Wu H (2010) Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling. Nature 465: 885–890.
  30. 30. Wang L, Yang JK, Kabaleeswaran V, Rice AJ, Cruz AC, et al. (2010) The Fas-FADD death domain complex structure reveals the basis of DISC assembly and disease mutations. Nature Structural & Molecular Biology 17: 1324–1329.
  31. 31. Weber CH, Vincenz C (2001) A docking model of key components of the DISC complex: death domain superfamily interactions redefined. FEBS letters 492: 171–176.
  32. 32. Krissinel E, Henrick K (2007) Inference of macromolecular assemblies from crystalline state. J Mol Biol 372: 774–797.
  33. 33. Bailey S (1994) The CCP4 suite: programs for protein crystallography. Acta Crystallogr D 50: 760–763.
  34. 34. Casademunt E, Carter BD, Benzel I, Frade JM, Dechant G, et al. (1999) The zinc finger protein NRIF interacts with the neurotrophin receptor p75(NTR) and participates in programmed cell death. EMBO J 18: 6050–6061.
  35. 35. Linggi MS, Burke TL, Williams BB, Harrington A, Kraemer R, et al. (2005) Neurotrophin receptor interacting factor (NRIF) is an essential mediator of apoptotic signaling by the p75 neurotrophin receptor. J Biol Chem 280: 13801–13808.
  36. 36. Esposito D, Sankar A, Morgner N, Robinson CV, Rittinger K, et al. (2010) Solution NMR investigation of the CD95/FADD homotypic death domain complex suggests lack of engagement of the CD95 C terminus. Structure 18: 1378–1390.
  37. 37. Khursigara G, Bertin J, Yano H, Moffett H, DiStefano PS, et al. (2001) A prosurvival function for the p75 receptor death domain mediated via the caspase recruitment domain receptor-interacting protein 2. J Neurosci 21: 5854–5863.
  38. 38. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J (2006) An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125: 1137–1149.
  39. 39. Tyurina YY, Nylander KD, Mirnics ZK, Portugal C, Yan C, et al. (2005) The intracellular domain of p75NTR as a determinant of cellular reducing potential and response to oxidant stress. Aging Cell 4: 187–196.
  40. 40. Mi Z, Rogers DA, Mirnics ZK, Schor NF (2009) p75NTR-dependent modulation of cellular handling of reactive oxygen species. J Neurochem 110: 295–306.
  41. 41. Battye TGG, Kontogiannis L, Johnson O, Powell HR, Leslie AGW (2011) iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM. Acta Crystallographica Section D: Biological Crystallography 67: 271–281.
  42. 42. Otwinowski Z, Minor W (1997) Processing of X-ray diffraction data collected in oscillation mode. Methods in Enzymology 276: 307–326.
  43. 43. Vagin A, Teplyakov A (1997) MOLREP: an automated program for molecular replacement. Journal of Applied Crystallography 30: 1022–1025.
  44. 44. Pranovich S, Achten H, de Vries B, van Wijk J (2005) Structural Sketcher: Representing and applying well-structured graphic representations in early design. International Journal of Architectural Computing 3: 75–92.
  45. 45. Perrakis A, Harkiolaki M, Wilson KS, Lamzin VS (2001) ARP/wARP and molecular replacement. Acta Crystallographica Section D: Biological Crystallography 57: 1445–1450.
  46. 46. Murshudov G, Vagin AA, Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallographica Section D: Biological Crystallography 53: 240–255.
  47. 47. Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallographica Section D: Biological Crystallography 60: 2126–2132.
  48. 48. Laskowski RA, MacArthur MW, Moss DS, Thornton JM (1993) PROCHECK: a program to check the stereochemical quality of protein structures. Journal of Applied Crystallography 26: 283–291.